Table 1.
Completed and available prospective/retrospective trials of RASi combine with other therapies to fight against cancer
| NCT number | Classified & Design | Interventions | Conditions | Outcome |
|---|---|---|---|---|
| NCT01805453 | CHT+RT+ARB; RCT | Losartan 50 mg*2/day | Newly-diagnosed | No results posted |
| Placebo | glioblastoma | |||
| NCT01434134 | CHT+RT+ARB; RCT | Metoprolol 100 mg/d | Breast cancer | No results posted |
| Placebo | Heart failure | |||
| Candesartan 32 mg/d | ||||
| NCT00459771 | Targeted therapy+ARB; RCT | Candesartan 32 mg/d | Breast cancer | No results posted |
| Placebo | ||||
| NCT00162955 | RT+ARB, RCT | Valsartan 80 mg/d | Non-hodgkin’s | Positive |
| lymphoma | ||||
| NCT01110824 | CHT+ACEI; RCT | Enalapril 2.5 to 10 mg/d | Acute myeloid leukemia | Positive |
| Carvedilol 6.25 to 25 mg | Lymphoid neoplasm | |||
| Multiple myeloma | ||||
| Lymphoma | ||||
| NCT02651415 | Targeted therapy+ACEI; Single arm | Regorafenibn 10 mg/d | Metastatic | Positive |
| Perindopril 4 mg/d | colorectal cancer | |||
| NCT00895414 | CHT+ACEI; RCT | Doxorubicin hydrochloride | Breast cancer | Positive |
| Enalapril maleate | ||||
| NCT01754909 | RT+ACEI; RCT | Enalapril 2.5, 5, or 10 mg | Lung cancer | Positive |
| escalating doses Placebo | Radiation pneumonitis |
RT: radiation therapy; RCT: randomized control therapy; CHT: chemotherapy.